Lung Cancer News and Research

Latest Lung Cancer News and Research

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

OncoGenex Pharmaceuticals, Inc. announced today it has filed an amendment with the U.S. Food and Drug Administration, as well as initiated filing with regulatory agencies in other countries, to amend the statistical design and analysis plan of its pivotal, international Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC).

30 Apr 2015

Scientists test effectiveness of new method for treating COPD

Scientists at Helmholtz Zentrum München have succeeded in testing the effectiveness of new approaches for treating chronic obstructive pulmonary disease (COPD) on ex vivo 3D human lung tissue cultures (3D-LTCs). The results have now been published in the European Respiratory Journal.

30 Apr 2015

Research provides insights into the ability of FL118 to overcome treatment resistance

The latest research from the team that discovered the novel anticancer agent FL118 highlights distinctive characteristics of this small-molecule compound and provides insights into its ability to overcome the persistent problem of treatment resistance. In findings reported in Molecular Cancer, Fengzhi Li, PhD, of Roswell Park Cancer Institute, and colleagues provide new evidence that FL118 may be more effective than two structurally similar injectable drugs and, additionally, may be effective as an oral agent.

30 Apr 2015

CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

Blood-based biomarkers such as circulating tumor cells (CTCs), circulating free DNA (cfDNA), circulating tumor DNA (ctDNA) and microRNAs (miRNAs) are potential indicators for the tumor burden of patients living with cancer.

30 Apr 2015

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Benitec Biopharma, a biopharmaceutical company focused on providing potentially curative therapies with its proprietary gene-silencing technology called ddRNAi or "expressed RNAi," is pleased to advise that the fifth patient in the company's 'first in man', Phase I/IIa dose escalation clinical trial of TT-034 for hepatitis C virus (HCV) infection, has today, been dosed at the Duke Clinical Research Unit.

29 Apr 2015

Researchers describe critical connection associated with environmental cause of silicosis, lung cancer

Researchers at the University of Louisville have detailed a critical connection associated with a major environmental cause of silicosis and a form of lung cancer. Their study is reported in today's Nature Communications.

29 Apr 2015

McMaster researchers explore how surgeon's experience influences choice of surgery for patients

Researchers at McMaster University (Hamilton, ON) explored whether a surgeon's expertise influences procedural choice. The results of a new study of more than 8000 non-small cell lung cancer (NSCLC) patients undergoing surgical resection by 124 physicians showed that surgeons who perform more surgeries are less likely to perform high-risk pneumonectomies. Christian J. Finley, MD, MPH, will be presenting the results of this research at the 95th AATS Annual Meeting in Seattle, WA on April 28, 2015.

29 Apr 2015

Innovative, active post-discharge intervention program benefits thoracic surgery patients

Post-surgical hospital readmission after discharge and repeat emergency room (ER) visits are not unusual for patients who have undergone major thoracic surgery. Recognizing this problem, clinicians at McMaster University have implemented an innovative, active post-discharge intervention for thoracic surgery patients that is based on the principle of a "one team-one approach" that is initiated while the patient is still hospitalized.

29 Apr 2015

Lung cancer surgery patients at higher risk of developing venous thromboembolism

New evidence suggests that lung cancer surgery patients are at higher risk of developing venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), than previously thought, with elevated risks of complications or death. When thromboemboli occur, they may be asymptomatic or attributed to post-surgical pain or complications, and may reflect both the lung cancer itself as well as compromised lung function after surgery.

29 Apr 2015

OncoGenex terminates agreement with Teva, regains rights to custirsen

OncoGenex Pharmaceuticals, Inc. today announced that its wholly owned subsidiary, OncoGenex Technologies Inc., executed a termination agreement with Teva Pharmaceuticals Ltd. under which OncoGenex will regain rights to custirsen, an investigational compound currently in Phase 3 clinical development as a treatment for prostate and lung cancers.

27 Apr 2015

New analysis finds that rates of health insurance coverage vary by demographics, cancer type

A new analysis has found that, among patients with cancer, rates of health insurance coverage vary by patient demographics and by cancer type. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings suggest that the expansion of coverage through the Affordable Care Act may disproportionally benefit certain patient populations.

27 Apr 2015

Researchers move one step closer to developing effective radiotherapy for lung cancer

Radiotherapy using protons can deliver more accurate treatment to a tumour while reducing the dose to surrounding tissue. However, in mobile organs such as the lung, precise targeting of the dose is difficult. Now researchers have succeeded in making a model of breathing movement that allows for the precise measurement of narrow beams to a dummy tumour by simulating the motion and physical properties of the chest anatomy in a model, the 3rd ESTRO Forum in Barcelona, Spain, will hear today (Monday).

27 Apr 2015

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.

25 Apr 2015

Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon

Without a doubt, one of the most significant developments in thoracic surgery was the advent of video-assisted thoracoscopic surgery or VATS in the 1990s...

22 Apr 2015

Sysmex Inostics to offer OncoBEAM CLIA laboratory services in Germany, Austria and Switzerland

Sysmex Inostics, a subsidiary of Sysmex Corporation, today announced that they have signed an exclusive distributor agreement with IndivuTest GmbH, and its parent company Indivumed GmbH, a cancer research company focused on the development of individualized cancer diagnostics and therapies.

From Sysmex America, Inc. 22 Apr 2015

Researchers uncover methylated DNA markers that may lead to noninvasive cancer screening

A team of Mayo Clinic researchers has succeeded in identifying the source of cancer in patients' gastrointestinal tracts by analyzing DNA markers from tumors. The results open the possibility that doctors could one day be able to screen for cancer anywhere in the body with a noninvasive blood test or stool sample.

22 Apr 2015

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

The PointMan EGFR DNA enrichment kit, a novel method for selective amplification of genotype specific sequences.

From EKF Diagnostics 21 Apr 2015

New Dream Team dedicated to ovarian cancer research formed at AACR Annual Meeting 2015

Stand Up To Cancer, Ovarian Cancer Research Fund, Ovarian Cancer National Alliance, and National Ovarian Cancer Coalition, along with the American Association for Cancer Research, Scientific Partner to SU2C, announced today the formation of a Dream Team devoted to ovarian cancer research at the AACR Annual Meeting 2015, held here April 18-22.

21 Apr 2015

Targeting PD-1/PD-L1 signaling may open up new therapy options for lung cancer patients

New findings about regulation of PD-L1, a protein that allows cancer to evade the immune system, has shown therapeutic promise for several cancers, including the most common form of lung cancer.

21 Apr 2015

Scientists reveal three major subsets of KRAS-mutant LUAC

Mutations of the KRAS gene are commonly known to lead to cancer. However, deeper understanding of exactly how they do this continues to be explored by cancer researchers.

20 Apr 2015

Lung Cancer News and Research

Latest Lung Cancer News and Research

OncoGenex provides update on Phase 3 ENSPIRIT trial evaluating custirsen for treatment of NSCLC

Scientists test effectiveness of new method for treating COPD

Research provides insights into the ability of FL118 to overcome treatment resistance

CANCER-ID consortium aims to set up standard procedures for clinical validation of blood-based biomarkers

Fifth patient dosed in Benitec's TT-034 Phase I/IIa clinical trial for prevention of HCV infection

Researchers describe critical connection associated with environmental cause of silicosis, lung cancer

McMaster researchers explore how surgeon's experience influences choice of surgery for patients

Innovative, active post-discharge intervention program benefits thoracic surgery patients

Lung cancer surgery patients at higher risk of developing venous thromboembolism

OncoGenex terminates agreement with Teva, regains rights to custirsen

New analysis finds that rates of health insurance coverage vary by demographics, cancer type

Researchers move one step closer to developing effective radiotherapy for lung cancer

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Advances in thoracic surgery: an interview with Dan Wildman, VP Global Franchise Strategy & Innovation- Ethicon

Sysmex Inostics to offer OncoBEAM CLIA laboratory services in Germany, Austria and Switzerland

Researchers uncover methylated DNA markers that may lead to noninvasive cancer screening

Data presented at AACR 2015 recognizes value of EKF PointMan technology for assessing lung cancer mutation status

New Dream Team dedicated to ovarian cancer research formed at AACR Annual Meeting 2015

Targeting PD-1/PD-L1 signaling may open up new therapy options for lung cancer patients

Scientists reveal three major subsets of KRAS-mutant LUAC

The ultimate guide to lung research tools and protocols eBook

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Newsletters you may be interested in